3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Raphael Pharmaceutical's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 6,094.12%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Raphael Pharmaceutical's 3-Year ROIIC % or its related term are showing as below:
RAPH's 3-Year ROIIC % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.72
vs RAPH: 6094.12
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Raphael Pharmaceutical 3-Year ROIIC % Related Terms
Raphael Pharmaceutical 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Raphael Pharmaceutical's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPH vs TXMD, AYTU, MRMD: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raphael Pharmaceutical 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Raphael Pharmaceutical's 3-Year ROIIC % falls into.
Raphael Pharmaceutical's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.245 (Dec. 2025) - -3.317 (Dec. 2022) )
/
( 0.036 (Dec. 2025) - 0.002 (Dec. 2022) )
=
2.072
/
0.034
=
6,094.12%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Raphael Pharmaceutical (RAPH) has a 3-Year ROIIC % of 6,094.12 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Raphael Pharmaceutical and its competitors. This is 94% above median its historical median of 3,135.23. Over the past decade, Raphael Pharmaceutical's 3-Year ROIIC % has ranged from 176.34 to 6,094.12.
Is Raphael Pharmaceutical's 3-Year ROIIC % too high?
Raphael Pharmaceutical's current 3-Year ROIIC % of 6,094.12 is 94% above median its 10-year median of 3,135.23. Over the past 10 years, this metric has ranged from a low of 176.34 to a high of 6,094.12. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Raphael Pharmaceutical's value of 6,094.12 is 163720.4% above this industry median. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's 3-Year ROIIC % compare to TXMD and AYTU?
Raphael Pharmaceutical's 3-Year ROIIC % of 6,094.12 can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year ROIIC % is 3.72. Raphael Pharmaceutical's value of 6,094.12 is 163720.4% above this benchmark. Historically, Raphael Pharmaceutical's own 3-Year ROIIC % has ranged from 176.34 to 6,094.12 over the past decade. While the company's 10-year median is 3,135.23 vs. the industry median of 3.72, Raphael Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raphael Pharmaceutical's current 3-Year ROIIC % of 6,094.12 is 163720.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Raphael Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raphael Pharmaceutical's current 3-Year ROIIC % is 6,094.12, which is 94% above median its own 10-year median of 3,135.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current 3-Year ROIIC % of 6,094.12. The current 3-Year ROIIC % is 6,094.12, which is 94% above median its 10-year median of 3,135.23 and 163720.4% above the Drug Manufacturers industry median of 3.72. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current 3-Year ROIIC % is 6,094.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score
Get the complete analysis for RAPH
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPH has been successfully added to your 
